Aura Biosciences, Inc. filings document a clinical-stage biotechnology issuer focused on precision therapies for solid tumors and its common stock listed on The Nasdaq Global Market under AURA. Form 8-K disclosures cover operating and financial results, corporate presentations, executive leadership changes, material agreements, and equity financing activity involving common stock and pre-funded warrants.
Proxy materials describe annual meeting proposals, director elections, auditor ratification, voting results, and board governance. The filing record also includes capital-structure disclosure, risk-factor disclosure, and updates tied to Aura’s clinical pipeline, including bel-sar (AU-011) in ocular oncology and bladder cancer indications.
Aura Biosciences, Inc. reported that BlackRock, Inc. beneficially owned 5,219,492 common shares, or 5.03% of the class, as of September 30, 2026. BlackRock reported sole voting power over 5,144,654 shares and sole dispositive power over 5,219,492 shares; shared voting and dispositive power were each zero.
The reported ownership reflects certain BlackRock business units and subsidiaries and affiliates, excluding securities attributed to other business units whose beneficial ownership is disaggregated. Various persons have rights to receive dividends or direct sale proceeds, but no one person's interest exceeds 5% of Aura Biosciences' outstanding common shares.
Aura Biosciences, Inc. reports that ForGrowth III PA B.V. directly owns 5,248,841 shares of common stock. Forbion Growth Opportunities Fund III Cooperatief U.A., the sole shareholder of ForGrowth III PA B.V., and Forbion Growth III Management B.V., which is director of both entities, may be deemed to share voting and investment power over those shares. The three reporting persons each report shared voting and dispositive power over 5,248,841 shares, with zero sole voting or dispositive power. The position represents approximately 5.1% of Aura's common stock, based on 103,704,809 shares outstanding as of August 6, 2026.
Aura Biosciences, Inc. (AURA) reported that Chief People Officer Julie Person received 107,611 shares of Common Stock in the form of restricted stock units (RSUs) as an inducement award, and a stock option for 212,389 shares with an exercise price of $7.43 per share.
The RSUs vest in four substantially equal annual installments starting September 15, 2027, conditioned on continued service. The stock option vests 25% on August 12, 2027, with the remaining 75% vesting pro-rata in 36 monthly installments, also subject to continued service, and expires on September 1, 2036.
Aura Biosciences, Inc. (AURA) reported that Chief Regulatory & Quality Officer Erica Kratz received equity awards on 2026-09-01. She was granted 100,885 restricted stock units as an inducement award, each representing one share of common stock, vesting in four substantially equal annual installments starting on September 15, 2027, subject to continued service. She also received a stock option for 199,115 shares of common stock at an exercise price of $7.43 per share, vesting 25% on August 10, 2027 with the remainder vesting pro rata in 36 monthly installments, and expiring on September 1, 2036. Following these awards, the filing reports holdings of 100,885 common shares and 199,115 stock options directly owned.
Aura Biosciences, Inc. (AURA) reported that Chief Medical Officer Janet Jill Hopkins received equity compensation awards. She was granted 58,850 RSUs, each representing one share of common stock upon vesting, and a stock option for 116,150 shares of common stock at an exercise price of $7.43 per share. The RSUs vest in four substantially equal annual installments starting September 15, 2027, and the option vests monthly over 48 months starting October 1, 2026, with an expiration date of September 1, 2036. Following these grants, she directly holds 380,190 common shares, excluding unexercised options.
Aura Biosciences, Inc. (AURA) reported that officer Amy Elazzouzi, SVP, Finance & PAO, received new equity awards. On 2026-09-01 she was granted 23,540 RSUs, each representing one share of common stock upon vesting, bringing her directly held common shares to 143,600. The RSUs vest in four substantially equal annual installments, with the first tranche vesting on September 15, 2027, subject to continued service. She was also granted a stock option for 46,460 shares of common stock at an exercise price of $7.43 per share, vesting as to 1/48th of the award monthly starting October 1, 2026, and expiring on September 1, 2036, also subject to continued service.
Aura Biosciences, Inc. (AURA) reported that Chief Operating Officer Susan Abu‑Absi received equity awards on 2026-09-01. She was granted 265,487 stock options with an exercise price of $7.43 per share, expiring on 2036-09-01, and 134,513 RSUs as an inducement award. The RSUs vest in four substantially equal annual installments starting on September 15, 2027, and the options vest 25% on August 10, 2027 with the remainder vesting pro rata in 36 monthly installments, in each case subject to continued service.
Aura Biosciences, Inc. received an updated ownership report from a group of Frazier Life Sciences-affiliated funds and individuals regarding its common stock. Frazier Life Sciences Public Fund, L.P. directly holds 5,807,260 shares of common stock, representing 5.6% of the class based on 103,436,416 shares outstanding as of June 12, 2026. Other Frazier funds directly hold additional shares, including 128,520 shares by Frazier Life Sciences X, L.P., 358,810 shares by Frazier Life Sciences XI, L.P., and 805,410 shares by Frazier Life Sciences XII, L.P. The filing also notes prefunded warrants held by these funds that are subject to a 9.99% beneficial ownership limitation, preventing exercises that would take any holder and its affiliates above that ownership threshold.
Aura Biosciences, Inc. has a significant shareholder group reported by Long Focus Capital Management, LLC and John Helmers under a Schedule 13G. As of the close of business on June 30, 2026, they reported beneficial ownership of 5,119,582 shares of Aura Biosciences common stock, representing 4.9% of the class.
They report no sole voting or dispositive power and shared voting and dispositive power over 5,119,582 shares, held in client accounts managed by Long Focus Capital Management, LLC. The manager states that no single client owns more than 5% of the class. John Helmers controls Long Focus Capital Management, LLC.